CD8A and neoplasm: In murine cancer models, intratumoral injection of ADU-S100 promoted the release of pro-inflammatory cytokines and enhanced infiltration of immune cells such as macrophages, CD8+ T cells, NK cells, and neutrophils into the TME, leading to a robust anti-tumor response while decreasing mortality [55,75,76].